The FKRP (Fukutin-Related Protein) gene encodes a glycosyltransferase essential for proper muscle and brain function by modifying α-dystroglycan.
Mutations in FKRP disrupt this glycosylation process, leading to a group of disorders known as dystroglycanopathies. These disorders range from mild muscular dystrophy to severe congenital conditions affecting the brain and eyes.
The FKRP gene encodes the fukutin-related protein, a glycosyltransferase located in the Golgi apparatus.
It is highly expressed in skeletal muscle, cardiac muscle, and the brain, where it modifies α-dystroglycan (α-DG) by adding ribitol 5-phosphate. This step in glycosylation is essential for α-DG’s ability to anchor muscle cells to surrounding tissues and guide neuron development during early brain formation.
The following sections describe the normal function of the protein associated with the FKRP gene.
FKRP helps build and maintain muscle integrity by supporting the glycosylation of α-dystroglycan, a protein that forms a structural bridge between the cell’s internal framework and the extracellular matrix.
Properly glycosylated α-dystroglycan is vital for the strength and stability of skeletal and cardiac muscle fibers. It also plays a role in neuron migration during early brain development.
Without FKRP function, α-dystroglycan is improperly glycosylated, leading to unstable muscle fibers and a spectrum of conditions called dystroglycanopathies, which range from mild muscle weakness to severe congenital syndromes affecting the brain and eyes.
The following scenarios may prompt FKRP genetic testing:
Consider testing in patients with:
Genetic testing can identify carriers and help guide family planning decisions in families with a known FKRP-related disorder.
FKRP testing aids in differentiating dystroglycanopathies from similar muscular dystrophies, including Duchenne and Becker.
Due to its autosomal recessive inheritance, counseling is essential for understanding risk, interpreting results, and managing family implications.
Specific FKRP mutations may provide important information about:
Identifying pathogenic variants confirms a diagnosis of FKRP-related muscular dystrophy.
Most FKRP disorders follow an autosomal recessive pattern. Both parents must be carriers for a child to be affected.
A negative FKRP test does not rule out muscular dystrophy. Other genes can cause similar symptoms. If clinical suspicion remains high, consider:
Testing for FKRP is often performed as a genetic test to look for mutations in the gene that would alter functional protein availability. The following section outlines the testing procedures and interpretation.
Genetic testing involves blood, saliva, or cheek swab samples, although specialized laboratories may recommend different sample types.
A cheek swab or saliva sample is easily obtained from the comfort of home, while blood samples typically require a blood draw.
Normal reference ranges for FKRP genetic testing are considered to be without mutations that can alter the activity of the FKRP proteins.
The clinical implications of a positive FKRP mutation test result will vary by individual, although FKRP mutations in symptomatic patients may signal a need for further assessment and possibly treatment, especially in the setting of symptoms associated with muscular dystrophies.
Patients or practitioners with questions about the clinical implications of FKRP mutations should seek further assessment with a genetic counselor or expert.
Click here to compare genetic test panels and order genetic testing for health-related SNPs.
Entry - *606596 - FUKUTIN-RELATED PROTEIN; FKRP - OMIM. (2019). Omim.org. https://omim.org/entry/606596
FKRP fukutin related protein [Homo sapiens (human)] - Gene - NCBI. (2025). Nih.gov. https://www.ncbi.nlm.nih.gov/gene/79147
FKRP gene: MedlinePlus Genetics. (n.d.). Medlineplus.gov. https://medlineplus.gov/genetics/gene/fkrp/
Fu, X., Yang, H., Wei, C., Jiao, H., Wang, S., Yang, Y., Han, C., Wu, X., & Xiong, H. (2016). FKRP mutations, including a founder mutation, cause phenotype variability in Chinese patients with dystroglycanopathies. Journal of Human Genetics, 61(12), 1013–1020. https://doi.org/10.1038/jhg.2016.94
Gedlinske AM, Stephan CM, Mockler SRH, Laubscher KM, Laubenthal KS, Crockett CD, Zimmerman MB, Mathews KD. Motor outcome measures in patients with FKRP mutations: A longitudinal follow-up. Neurology. 2020 Oct 13;95(15):e2131-e2139. doi: 10.1212/WNL.0000000000010604. Epub 2020 Aug 6. PMID: 32764098; PMCID: PMC7713753.
Jensen, S. M., Kai Ivar Müller, Svein Ivar Mellgren, Bindoff, L. A., Rasmussen, M., Ørstavik, K., Christoffer Jonsrud, Tveten, K., Nilssen, Ø., Marijke Van Ghelue, & Kjell Arne Arntzen. (2023). Epidemiology and natural history in 101 subjects with FKRP-related limb-girdle muscular dystrophy R9. The Norwegian LGMDR9 cohort study (2020). Neuromuscular Disorders, 33(2), 119–132. https://doi.org/10.1016/j.nmd.2022.11.005
Vajsar J, Schachter H. Walker-Warburg syndrome. Orphanet J Rare Dis. 2006 Aug 3;1:29. doi: 10.1186/1750-1172-1-29. PMID: 16887026; PMCID: PMC1553431.
Qualtieri, A., De Benedittis, S., Cerantonio, A., Citrigno, L., Di Palma, G., Gallo, O., Cavalcanti, F., & Spadafora, P. (2024). Molecular Study of the Fukutin-Related Protein (FKRP) Gene in Patients from Southern Italy with Duchenne/Becker-like Phenotype. International Journal of Molecular Sciences, 25(19), 10356. https://doi.org/10.3390/ijms251910356